The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. MorphoSys AG's quick ratio for the quarter that ended in Dec. 2023 was 2.84.
MorphoSys AG has a quick ratio of 2.84. It generally indicates good short-term financial strength.
The historical rank and industry rank for MorphoSys AG's Quick Ratio or its related term are showing as below:
XSWX:MOR'
s Quick Ratio Range Over the Past 10 Years
Min: 2.84 Med: 6.56 Max: 10.91
Current: 2.84
During the past 13 years, MorphoSys AG's highest Quick Ratio was 10.91. The lowest was 2.84. And the median was 6.56.
XSWX:MOR's Quick Ratio is ranked worse than 56.89% of 1554
companies
in the Biotechnology industry
Industry Median: 3.57
vs XSWX:MOR: 2.84
MorphoSys AG Quick Ratio Historical Data
The historical data trend for MorphoSys AG's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of MorphoSys AG's Quick Ratio
For the Biotechnology subindustry, MorphoSys AG's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MorphoSys AG's Quick Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MorphoSys AG's Quick Ratio distribution charts can be found below:
* The bar in red indicates where MorphoSys AG's Quick Ratio falls into.
MorphoSys AG Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
MorphoSys AG's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MorphoSys AG (XSWX:MOR) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
MorphoSys AG Quick Ratio Related Terms
Thank you for viewing the detailed overview of MorphoSys AG's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XSWX:MOR has been successfully added to your 